Цитофлавин is a neuroprotective and metabolic therapy generally utilized to provide supportive relief and functional assistance across several neurological and vascular domains where symptoms are related to systemic imbalance and organ-specific functional stress. The medication's therapeutic role includes management of conditions such as acute ischemic stroke and its sequelae.

It is relevant in contexts involving heightened systemic burden, such as hypoxic or toxic encephalopathies, and is applied in addressing the symptom clusters associated with chronic cerebral ischemia and stroke sequelae. It is also considered relevant in clinical settings for easing specific complaints associated with metabolic complications, including the numbness and burning pain of diabetic polyneuropathy, and is applied in addressing symptom clusters related to pathological fatigue (neurasthenia).

“The medication’s role is to offer symptomatic relief that helps patients cope more steadily during difficult episodes and assists with maintaining a sense of functional stability.”

Quick Fact: Symptomatic Support

The medication assists with managing symptoms related to memory, attention, and concentration issues, and is relevant for easing discomfort that may interfere with daily functioning during symptomatic periods.

Regulatory References

1. Government Drug Assessment Report

Who Can and Cannot Use Цитофлавин?

Regulatory documents strictly define the population eligibility for Цитофлавин (Cytoflavin) use.

Absolute Contraindications (Must Not Use)

Use is prohibited for patients with known hypersensitivity to any active component (Inosine, Nicotinamide, Riboflavin, Succinic Acid) or excipients. The medicine is also contraindicated for women during pregnancy and breastfeeding due to a lack of supporting clinical data. Further non-eligibility rules apply to critically ill patients until central hemodynamic parameters are stabilized and to any patient with severe arterial hypoxemia (oxygen partial pressure below 60 mmHg).

Age and Condition-Based Restrictions

The oral tablet form is contraindicated for children and adolescents under 18 years old. However, the intravenous solution is permitted only in the neonatal period for the treatment of cerebral ischemia, representing a highly restricted pediatric allowance. Adults aged 18 and older are eligible for standard use.

Use requires caution in patients with comorbidities such as gout, hyperuricemia, nephrolithiasis (kidney stones), and those with renal or hepatic impairment. Diabetic patients must only use the medicine under the strict control of blood glucose indicators as required by the official label.

Interaction Map: Interactions with other medicines and products — official regulatory information for Цитофлавин

Interaction Scope

Interaction Classifications (High-Level)

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Ethanol (alcohol) is documented to inhibit the effect of Цитофлавин.
• The Riboflavin component reduces the activity of Sulfonamide preparations.
• The Riboflavin component reduces the efficacy of Tetracycline-group antibiotics.
• The Inosine component may potentiate the effects of certain hypotensive medicinal products.
• Additive pharmacological effects may result from co-administration with products containing Nicotinamide or Riboflavin.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define the product’s interaction structure primarily through documented exposure modification and pharmacodynamic potentiation attributed to the vitamin co-factors and Inosine component. The profile is structured around the required management of the documented reduced efficacy of co-administered antibiotics and sulfa drugs, and an explicit substance interference restriction with alcohol.

Цитофлавин (Cytoflavin) is a combination drug whose mechanism of action involves the synergistic modulation of cellular bioenergetic and redox pathways across multiple tissues, with selective accumulation observed in neuronal and glial cells. The succinic acid component acts as a direct substrate for the succinate dehydrogenase enzyme (Complex II) within the mitochondrial electron transport chain (ETC) and Krebs cycle. This interaction facilitates accelerated flow through the ETC, resulting in enhanced mitochondrial respiration and ATP synthesis. The riboflavin component is a precursor for the coenzymes Flavin Adenine Dinucleotide (FAD) and Flavin Mononucleotide (FMN). FAD and FMN serve as essential cofactors for multiple oxidoreductases, including Complex I and Complex II of the ETC and glutathione reductase, an enzyme pivotal in the cellular antioxidant defense system. The nicotinamide component serves as a precursor for Nicotinamide Adenine Dinucleotide (NAD+), a coenzyme necessary for numerous metabolic and redox reactions. The inosine component functions as a precursor for purine nucleotides, which are required for the salvage pathway of adenine nucleotide synthesis, contributing to the replenishment of the cellular ATP pool. The resultant downstream cascades include a reduction in reactive oxygen species (ROS) burden and an overall modulation of systemic tissue oxygen consumption.

How to Use Цитофлавин

Цитофлавин (Cytoflavin) is administered through two methods, each corresponding to its specific dosage form: as an Intravenous (IV) Infusion for acute use and as Enteric-Coated Tablets for long-term use, corresponding to standard prescribing information.

Administration Guidelines

The usage protocol is structured by the form and delivery requirements:

Key Procedural Requirements

For the Intravenous Infusion, the 10 mL concentrate must be diluted in 200 mL to 400 mL of a suitable solution, such as 0.9% Sodium Chloride or 5% Glucose solution, and administered slowly at a rate of 60 to 80 drops per minute. This requires medical supervision and is typically conducted in a hospital setting.

Oral Tablets are subject to timing requirements: they must be taken no less than 30 minutes before meals, swallowed whole, and should not be taken later than 18:00 (6 PM). The enteric coating must remain intact; tablets must not be chewed, split, or crushed. Technical labeling also specifies dose adjustments for specific groups, such as a 2 mL/kg dose for cerebral ischemia in newborns, administered after dilution.

This two-part procedural structure dictates whether the medicine is used intensively in an acute setting or cyclically for long-term maintenance, ensuring use adheres to the specific preparation and timing constraints.

Research Evidence / Overview of Studies for Цитофлавин

The information in this section summarizes the structure and focus of clinical studies that have been conducted on Цитофлавин (Cytoflavin), detailing what outcomes were monitored in trials and what aspects of the medicine's research remain limited or uncertain. This summary is intended for informational purposes only and does not contain clinical advice or claims about effectiveness.

Evidence for Use in Acute Ischemic Stroke Recovery

The medicine was studied for use in individuals during the acute phase and the rehabilitation period following an ischemic stroke. The available research includes Randomized Controlled Trials (RCTs) and open comparative studies involving adults, including older adults, designed to evaluate use alongside standard care. Researchers primarily examined outcomes related to functional recovery and neurological status, monitoring changes in the severity of neurological deficit and tracking outcomes reflecting daily functioning using standardized scales.

Findings describe patterns observed in the studies over follow-up periods of up to 90 days. However, certain trials was observed in some studies to use open designs, where blinding was not implemented. This can introduce potential uncertainty compared to fully blinded research.

Evidence for Use in Diabetic Polyneuropathy Symptoms

Цитофлавин was studied for use in conditions associated with acute or disruptive episodes of nerve pain and discomfort related to Type 2 Diabetes. The research structure for this area is characterized by Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trials.

The primary focus of these trials was applied in studies examining patient-reported experiences. Studies monitored changes in the Total Symptom Score (TSS), which is used in research exploring how symptoms change over time, specifically for feelings like burning and numbness over a 12-week period. Research also explored outcomes related to quality of life.

What is Still Uncertain About Цитофлавин Evidence

A common pattern across the research is that follow-up durations were limited, meaning that long-term effects are not fully established across the main areas of investigation. Evidence is limited for outcomes beyond the short-term trial periods. Additionally, the results apply only to the populations studied, and data for certain groups remain insufficient (e.g., individuals with Type 1 Diabetes or severe symptom burdens). The use of subjective, patient-reported outcomes in conditions like DPN means that the findings help contextualize how patients reported their experience but are less objective than physiological measures.

Key Studies & References

1. Government Drug Assessment Report: Therapeutic Role in Acute Ischemic Stroke and Sequelae

Common questions about Цитофлавин (FAQ)

Q: What's the difference between Цитофлавин tablets and the intravenous solution?

A: The official product information defines two distinct methods of administration. The intravenous solution is typically reserved for acute phases, such as post-stroke recovery, and requires administration under medical supervision. The tablets are used for long-term or cyclical maintenance courses.

Q: Is Цитофлавин safe to use if I have kidney issues?

A: Regulatory information indicates that use should be approached with caution in patients who have renal impairment. Specific constraints apply for use in severe renal failure, particularly regarding the need to limit fluid volume during intravenous administration.

Q: Why is the mechanism of action of Цитофлавин described as 'metabolic'?

A: It is classified as metabolic because its components act as substrates and cofactors that are directly involved in the body’s energy production and protective chemical processes. The mechanism of action involves the modulation of cellular metabolism, particularly within the nervous system.

Q: Can Цитофлавин be taken along with regular multivitamins?

A: Official labeling cautions that additive pharmacological effects may occur if Цитофлавин is taken concurrently with products containing Nicotinamide (Vitamin B3) or Riboflavin (Vitamin B2), as these are components of the medication. Consultation with a healthcare provider is generally recommended when co-administering any medication with multivitamins containing these components.

Q: Does Цитофлавин interact negatively with common pain relievers like ibuprofen?

A: Official regulatory documents list documented interactions with Sulfonamide preparations, Tetracycline-group antibiotics, and certain Hypotensive Agents. Specific non-listed medications, such as common pain relievers like ibuprofen, are not addressed in the official interaction profile.

Q: Is Цитофлавин considered a vitamin or a full medication?

A: Цитофлавин is classified as a prescription medication—specifically, a combined metabolic drug with neuroprotective properties. Although it contains derivatives of B vitamins (Riboflavin and Nicotinamide) and a natural substrate, it is regulated and utilized as a pharmacological product.

Q: Are there any common but minor side effects I should expect when starting Цитофлавин?

A: Official regulatory documents list documented reactions that may occur, including abdominal discomfort, insomnia, and a short-term rise in arterial pressure. These documented effects are often described as short-term or transient.

Q: Can Цитофлавин help with general fatigue or just neurological problems?

A: Official indications and research evidence focus on use in neurological conditions, such as stroke recovery and symptoms of diabetic polyneuropathy. Use for general fatigue not linked to these specific conditions is not addressed in regulatory documentation.

Q: Is it normal to feel a bit flushed or warm after taking the first dose of Цитофлавин?

A: A feeling of heat or flushing is a documented adverse reaction, especially if the intravenous infusion rate is exceeded. The feeling is generally described as temporary.

Q: Why do doctors sometimes recommend Цитофлавин after a stroke or head injury?

A: The medicine is indicated as an adjunctive therapy for moderate acute ischemic stroke and its long-term sequelae. Its use is based on its neuroprotective and metabolic properties, which are studied for supporting cellular function during and after ischemic events.

Q: Does Цитофлавин have any effect on blood pressure or heart rate?

A: A short-term rise in arterial pressure is listed as a documented adverse reaction to Цитофлавин. General effects on heart rate are not specifically detailed in the official safety profile.

Q: Is Цитофлавин the same thing as a nootropic or 'brain supplement'?

A: No, it is a prescription medication classified as a combined metabolic and neuroprotective drug. This classification distinguishes it from general dietary supplements or products marketed as nootropics.

Q: Can taking Цитофлавин affect the results of blood tests?

A: The label notes that Riboflavin may cause intense yellow coloration to the urine. Specific effects on blood test results are not generally documented in the official safety profile. However, Inosine is a component that is metabolized to uric acid.

Q: Can Цитофлавин cause sleep disturbances or insomnia?

A: Yes, insomnia is listed in the official regulatory documents as a documented adverse reaction that may occur during treatment.

Q: How long does Цитофлавин stay in your system after you stop taking it?

A: The body processes and eliminates the individual components at different rates. For instance, intravenously administered components like Succinic acid are rapidly utilized. Nicotinamide is metabolized in the liver and excreted through the kidneys.

Q: Can Цитофлавин improve concentration and memory in healthy individuals?

A: Official research and clinical trials focus on improving cognitive function in patients with medical conditions. Use for cognitive enhancement in healthy individuals is not an official research focus or indicated use.

Q: Is there a maximum time frame for safely using Цитофлавин?

A: The official dosing protocols define specific course durations, such as 10 consecutive days for the IV form or 25 days for the oral form, typically followed by an interval. A maximum cumulative lifetime duration for use is not explicitly defined in regulatory documents.

Q: Is it possible for Цитофлавин to cause stomach upset?

A: Yes, gastrointestinal disorders are listed as a documented adverse reaction. Specifically, the official safety profile mentions abdominalgia, which refers to abdominal discomfort or pain.

Q: Is there any difference in bioavailability between the oral and IV forms of Цитофлавин?

A: The IV solution is designed for rapid systemic distribution and utilization of the active ingredients. The oral tablets have an enteric coating to control how the medicine is absorbed.

Q: What research is currently being done on new uses for Цитофлавин?

A: Current records indicate research and trials are focused on its use in complex rehabilitation following stroke, the management of diabetic polyneuropathy, and the prevention of cognitive decline after major surgery.

Q: Is Цитофлавин primarily used for nerve damage or poor blood flow to the brain?

A: The drug is indicated for conditions related to poor blood flow (e.g., ischemic stroke) and is studied for nerve damage symptoms (e.g., diabetic polyneuropathy).

Q: What is the expected time frame to notice benefits for memory issues when taking Цитофлавин?

A: Clinical trials for conditions involving cognitive function typically monitor the outcomes of patients over established follow-up periods, often ranging from 32 days to 12 weeks.

Q: Is it safe to drive or operate machinery while taking Цитофлавин?

A: The official regulatory documents contain a specific section on the medicine's potential effects on the ability to drive and operate machinery, which should be consulted.

Q: Is the effectiveness of Цитофлавин supported by high-quality randomized controlled trials (RCTs)?

A: The available research overview notes that studies for Цитофлавин include Randomized Controlled Trials (RCTs) for stroke recovery and Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trials for diabetic polyneuropathy.

Q: What are the signs that Цитофлавин is actually working for my condition?

A: In clinical trials, researchers monitored objective outcomes such as changes in the severity of neurological deficit and tracking functions of daily living. For nerve pain, studies monitored changes in patient-reported symptoms like burning and numbness.

Q: Is there a simplified way to understand the 'neuroprotective' aspect of the drug?

A: The 'neuroprotective' action means the drug helps protect nerve cells from damage. It achieves this by boosting the cells' internal energy production (ATP synthesis) and helping them manage cellular stress and oxygen deprivation.

Official Storage and Disposal Requirements

All storage and disposal rules for Цитофлавин (Cytoflavin) are strictly governed by regulatory documentation to ensure product stability and safety.

Regulatory documents mandate that the product is protected from both high temperatures and light exposure to preserve the medicine's integrity. Specific instructions are provided for discarding expired or unused medicine and its glass container.